Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management.

Anthracyclines remain a cornerstone therapy for haematological malignancies and solid tumours, but their use is limited by cardiotoxicity, ranging from asymptomatic left ventricular dysfunction to overt heart failure (HF). The risk increases with cumulative doxorubicin-equivalent exposure exceeding 250-300 mg/m2, although susceptibility varies substantially according to patient characteristics, pre-existing cardiovascular disease, genetic predisposition, and modifiable risk factors. Clinically overt HF occurs in ∼6-9% of patients, while subclinical cardiac dysfunction develops in up to 18%. The pathophysiology is multifactorial, involving interconnected mechanisms that disrupt cardiomyocyte homeostasis and promote endothelial dysfunction, inflammation, fibrosis, and adverse remodelling. Yet evidence connecting molecular mechanisms with long-term HF outcomes in humans remains incomplete. Risk stratification, incorporating clinical variables, cardiac biomarkers, echocardiography and, when appropriate, cardiac magnetic resonance enables earlier recognition of cardiac dysfunction. Trials of preventive neurohormonal treatment and statins have produced heterogeneous results, often relying on imaging rather than clinical HF endpoints. Once cardiac dysfunction develops, prompt initiation of foundational HF treatment and multidisciplinary decisions on cancer therapy are essential. Early detection and prompt initiation of HF therapies may reverse myocardial dysfunction, whereas delayed recognition is associated with a poorer treatment response and prognosis. This narrative review integrates current evidence on the mechanisms, risk stratification, surveillance, prevention, and management of anthracycline cardiotoxicity and HF, while highlighting gaps in knowledge, emerging therapeutic strategies, and future directions for clinically meaningful, risk-guided research.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/eschf/xvag284
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management.

Sanja Dj Stankovic, Gianluigi Savarese, Gordana Krljanać, Ovidiu Dragomir Chioncel et al.
PubMed
Chemotherapy-induced cardiotoxicity and mitigation
article

Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management.

Sanja Dj Stankovic, Gianluigi Savarese, Gordana Krljanać, Ovidiu Dragomir Chioncel, Marija M. Polovina, Mihajlo Viduljević, Marianna Adamo, Petar M Seferovic, Oliviana Dana Geavlete, Magdy Abdelhamid, Marija Zdravkovic, Milenko Tomić
article en

Abstract

Anthracyclines remain a cornerstone therapy for haematological malignancies and solid tumours, but their use is limited by cardiotoxicity, ranging from asymptomatic left ventricular dysfunction to overt heart failure (HF). The risk increases with cumulative doxorubicin-equivalent exposure exceeding 250-300 mg/m2, although susceptibility varies substantially according to patient characteristics, pre-existing cardiovascular disease, genetic predisposition, and modifiable risk factors. Clinically overt HF occurs in ∼6-9% of patients, while subclinical cardiac dysfunction develops in up to 18%. The pathophysiology is multifactorial, involving interconnected mechanisms that disrupt cardiomyocyte homeostasis and promote endothelial dysfunction, inflammation, fibrosis, and adverse remodelling. Yet evidence connecting molecular mechanisms with long-term HF outcomes in humans remains incomplete. Risk stratification, incorporating clinical variables, cardiac biomarkers, echocardiography and, when appropriate, cardiac magnetic resonance enables earlier recognition of cardiac dysfunction. Trials of preventive neurohormonal treatment and statins have produced heterogeneous results, often relying on imaging rather than clinical HF endpoints. Once cardiac dysfunction develops, prompt initiation of foundational HF treatment and multidisciplinary decisions on cancer therapy are essential. Early detection and prompt initiation of HF therapies may reverse myocardial dysfunction, whereas delayed recognition is associated with a poorer treatment response and prognosis. This narrative review integrates current evidence on the mechanisms, risk stratification, surveillance, prevention, and management of anthracycline cardiotoxicity and HF, while highlighting gaps in knowledge, emerging therapeutic strategies, and future directions for clinically meaningful, risk-guided research.

PubMed
Serbian Academy of Sciences and Arts (RS), University of Kragujevac (RS), Cairo University (EG), Carol Davila University of Medicine and Pharmacy (RO), Karolinska Institutet (SE), University of Belgrade (RS), Stockholm South General Hospital (SE), Univerzitetski Klinički Centar Srbije (RS), University Hospital Medical Center Bezanijska kosa (RS), University of Brescia (IT)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon